Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $708.66 million for the quarter ended September 2024, missing the Zacks Consensus ...

Exact Sciences (NASDAQ:EXAS) has filed a lawsuit in federal court alleging that Geneoscopy’s ColoSense product infringes upon a key patent for its colorectal cancer screening test Cologuard.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

When testing confirms this is true, it empowers them, allowing their care team to develop prevention and early detection plans for them.” For genetic testing to be helpful, it’s important to test for ...

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point Exact Sciences Q3 EPS loss of $0.21 fell short of analyst ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...